Navigation Links
Pharmacyclics Reports First Quarter 2013 Results
Date:5/1/2013

Company believes the presentation of non-GAAP financial measures provides useful information to management and investors regarding various financial and business trends relating to our financial condition and results of operations. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of our ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. To the extent this release contains historical non-GAAP financial measures, the Company has also provided corresponding GAAP financial measures for comparative purposes. Reconciliation between certain GAAP and non-GAAP measures is provided below.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements, including our expected liquidity position and timing of the receipt of certain milestone payments, and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "goal", "should", "would", "project", "plan", "predict", "intend", "target" and similar exp
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
2. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
3. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
4. Pharmacyclics, Inc. Prices Public Offering of Common Stock
5. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
6. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
7. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
8. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
9. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
10. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
11. Hospira Reports First-Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Ore. , July 25, 2014  Semler ... an emerging medical risk assessment company that develops ... patients and evaluating chronic diseases, today reported financial ... ended June 30, 2014. "The ... for Semler," said Doug Murphy-Chutorian , M.D., ...
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- Dr. Michael Gabriel ... Pediatrics, reacts to a recent study, which shows how grief ... - http://photos.prnewswire.com/prnh/20140723/129709 According to ... stress are more likely than others to grow up overweight ... There were two specific types of stress that ...
(Date:7/24/2014)... Wis. , July 24, 2014  Restore ... specialty and compounded pharmaceuticals, announced that it is ... information unique to each individual based upon their ... possible by understanding the interaction between a patient,s ... "We,re very excited to provide this new ...
Breaking Medicine Technology:Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3
(Date:7/25/2014)... 25, 2014 Florida Hospital and MOSI officially ... organizations for years to come and make a difference in ... $2 million dollar check to provide the support needed to ... enable MOSI to transform the IMAX Dome Theatre from film ... the only IMAX Dome Theatre in the state of Florida, ...
(Date:7/25/2014)... human brain can preserve oxygen to protect itself from ... Although dehydration significantly reduces blood flow to the ... compensates by increasing the amount of oxygen it extracts ... understand a lot more about how the human brain ... author Steven Trangmar, a researcher at Brunel University, said ...
(Date:7/25/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Ibuprofen and Oxcarbazepine Tablets . ... of Ibuprofen and one lot of Oxcarbazepine Tablets, by American ... packaging. Oxcarbazepine is used for the treatment of certain types ... reason for the recall is that Lot #142588, Expiration Date, ...
(Date:7/25/2014)... 25, 2014 A new study conducted by ... that 39 percent of all children in the survey under the ... survey looked at 2,505 children during the years of 2011 and ... of age. The final result was that about two out ... of these children were from lower-income families and were of East ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 A new study ... results of which are published today in Cancer , ... 55 and 74 who had an abnormal finding on a ... reduced quality of life than did those who were screened ... as a surprise to the researchers. “We expected that participants ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 4Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 5
... in the Jan. 10 edition of the New England ... treatment and diagnosis of LAM, or lymphangioleiomyomatosis, a progressive ... childbearing years. There currently are no treatments for ... may be going misdiagnosed or undiagnosed. , Researchers ...
... Medicine professor of neurology, Peter Whitehouse, M.D., Ph.D., challenges ... new book, The Myth of Alzheimers: What You Arent ... provocative and ground-breaking new book, Dr. Whitehouse questions current ... brings a new understanding to everything we thought we ...
... The Quantum Group,Inc. (Amex: QGP, QGP.U) ... by Paulson Investment Company, a wholly owned subsidiary ... the lead underwriter for the,December 2007 public offering, ... will separate into its individual component parts; three,shares ...
... Inc. (AIM: TYR), the,pioneer of safer, effective ... achieved development and financial milestones from Arysta,LifeScience ... exclusive global,licensing and co-development agreement to manufacture ... certain horticultural markets., TyraTech is developing ...
... Jan. 10 With an eye to helping,customers ... ( http://www.bragada.com ) is now packing its Luxury ... features than before., All Bragada Luxury mattresses ... built into the fabric. One of the softest ...
... 9 The perception that,U.S. doctors are unwilling to ... untrue, according to a new study funded by HHS, ... doctors think that current systems to report and share,information ... with their colleagues. Consequently, important information,about medical errors and ...
Cached Medicine News:Health News:New research demonstrates potential diagnosis, treatment benefits 2Health News:New research demonstrates potential diagnosis, treatment benefits 3Health News:New research demonstrates potential diagnosis, treatment benefits 4Health News:International brain aging expert challenges the existence of Alzheimer's as a 'disease' 2Health News:International brain aging expert challenges the existence of Alzheimer's as a 'disease' 3Health News:The Quantum Group, Inc. Announces Separation of Units 2Health News:The Quantum Group, Inc. Announces Separation of Units 3Health News:TyraTech Achieves Insecticide Development and Financial Milestones With Partner Arysta LifeScience 2Health News:TyraTech Achieves Insecticide Development and Financial Milestones With Partner Arysta LifeScience 3Health News:Bragada(R) Luxury Mattress, Inc. Upgrades Luxury and Ultra Luxury Collections 2Health News:Physicians Want to Learn From Medical Mistakes But Say Current Error-Reporting Systems are Inadequate 2Health News:Physicians Want to Learn From Medical Mistakes But Say Current Error-Reporting Systems are Inadequate 3
Accommodates either eye. Slotted, malleable aluminum surface. Correct size holes produce ideal pin hole effect. Packaged 50 per box....
Blue plastic shield for reduced glare. Packaged 12 per box....
Non-reflective black anodized aluminum. Selection of five pin hole sizes (0.8 mm to 1.5 mm). Overall length: 4.0 inches....
4 mm x 4 mm downward biting jaws, curved right, length of shaft 115 mm, overall length 9.3 inches....
Medicine Products: